Chardan Capital Cuts SAB Biotherapeutics (NASDAQ:SABS) Price Target to $20.00

SAB Biotherapeutics (NASDAQ:SABS) had its price target reduced by analysts at Chardan Capital from $25.00 to $20.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, SAB Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $11.40.

SAB Biotherapeutics Stock Down 5.7 %

SABS stock opened at $1.40 on Tuesday. SAB Biotherapeutics has a 12 month low of $1.36 and a 12 month high of $5.01. The company has a 50-day moving average price of $1.98 and a 200 day moving average price of $2.83. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. HB Wealth Management LLC lifted its stake in SAB Biotherapeutics by 118.6% during the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after acquiring an additional 128,800 shares during the period. Kovitz Investment Group Partners LLC purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at approximately $52,000. Northern Trust Corp acquired a new stake in SAB Biotherapeutics in the 4th quarter worth about $43,000. Geode Capital Management LLC raised its holdings in shares of SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after acquiring an additional 12,692 shares during the last quarter. Finally, Diadema Partners LP purchased a new position in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $114,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.